Takeda Lowers 2025 Outlook Due to Weak Q2 and Pipeline Impairment Charges

Takeda Pharmaceutical Company reported Q2 2025 adjusted net profit of 201.6 billion Japanese yen ($1.31 billion), missing analyst expectations. Total sales were $7.52 billion, below consensus estimates. The company lowered its full-year 2025 outlook due to foreign exchange impacts and impairment charges. Core revenue guidance was revised to 4.50 trillion yen, and core operating profit is expected to be 1.13 trillion yen.